Skip to main content
Caplight Logo









Prolacta Bioscience

Prolacta Bioscience

Private
Duarte, CaliforniaHealthcare & Life Scienceshttps://www.prolacta.com/en/

Last Round

M&A

Dec 30, 2024

Total Funding Raised

$80.9M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Prolacta Bioscience is a life sciences company that develops and manufactures human milk-based nutritional products for critically ill and premature infants in neonatal intensive care units.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

human milk-based nutritionneonatal intensive careNICUhuman milk fortifierdonor human milknecrotizing enterocolitisNECpreterm infant nutritionclinical nutritionextremely low birth weightELBWhuman milk bankneonatal nutritionhospital nutritionbreast milk bank

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Prolacta Bioscience Comparables

Compare Prolacta Bioscience with similar companies based on industry and business-model similarity.

Prolacta Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LactaLogics
78%
Abbott Laboratories
78%
Medolac Laboratories
76%

Prolacta Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&ADec 30, 2024
Series EMay 14, 2018
Series EDec 6, 2016
Series DNov 3, 2011
Series CMay 23, 2007
Series B
Oct 4, 2006

Key People

Founding team and executive leadership

Scott Elster

CEO

Executive Team

David Steinberg

Chief Financial Officer

Executive Team

Prolacta Bioscience Investors

Notable investors and investment history

Prolacta Bioscience investors
InvestorRounds
DFJ FrontierSeries C
EW Healthcare PartnersM&A, Series E
Gideon Hixon FundSeries C
Aisling CapitalSeries E
Draper AssociatesSeries C
PhillipCapital GroupSeries C
Arcturus CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 328, 101% of current headcount.

  • Dec 30, 2024

    EW Healthcare Partners led the M&A round.

Prolacta Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Prolacta Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Prolacta Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersDuarte, California
Employee Range326
Year Founded1999
Last FundingDec 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?